Caitlin F Lim, DO
Urology · Santa Cruz
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Dignity Health Medical Foundation · 1,211 clinicians in this group
Hospitals listed: Dominican Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lim’s office at (831) 533-1911 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$177,283
Medicare paid this office $177,283 for 367 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 211 | $39,147 | $101 |
| Botox | 29 | $18,451 | None |
| New patient visit (45+ min) | 131 | $17,280 | $132 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 29 | $11,268 | $322 |
| Diagnostic exam of bladder and urethra using an endoscope | 49 | $11,209 | $204 |
See all 20 services
| Return visit (30+ min) | 211 | $39,147 | $101 |
| Botox | 29 | $18,451 | None |
| New patient visit (45+ min) | 131 | $17,280 | $132 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 29 | $11,268 | $322 |
| Diagnostic exam of bladder and urethra using an endoscope | 49 | $11,209 | $204 |
| Injectable bulking agent, synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies | 14 | $6,695 | $209 |
| Insertion of lower leg neurostimulator electrode | 17 | $6,401 | $91 |
| Injection of implant material beneath lining of bladder and/or urethra using an endoscope | 14 | $5,926 | $312 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 16 | $5,083 | $318 |
| New patient visit (60+ min) | 28 | $4,886 | $174 |
| Short return visit (20+ min) | 57 | $4,801 | $73 |
| Insertion of sacral nerve neurostimulator electrode array | 15 | $4,323 | $240 |
| Long return visit (40+ min) | 27 | $4,133 | $143 |
| Insertion of device into abdomen with pressure and urine flow rate study | 16 | $2,771 | $173 |
| Insertion or replacement of peripheral, sacral, or gastric neurostimulator generator or receiver | 12 | $2,760 | $212 |
| Urinalysis, manual test | 287 | $2,018 | $3 |
| Ultrasound measurement of bladder capacity after voiding | 159 | $1,868 | $10 |
| Simple bladder irrigation and/or instillation | 11 | $1,326 | $66 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 16 | $445 | $28 |
| Electronic assessment of bladder emptying | 11 | $67 | $6 |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
| Removal of skin lesions | 1-10 | None |
Who their Medicare patients are
367 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 14% · Women 84% · Also on Medicaid 22% · Health risk score 1.24. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 69% · Depression 31% · Diabetes 21% · Atrial fibrillation 19% · Coronary heart disease 18% · Chronic kidney disease 18% · Heart failure 14% · COPD 13% · Cancer 12% · Stroke 7% · Dementia 5%.
The office billed $877,946, Medicare allowed $232,214 and paid $177,283; for 5,739 services of 65 kinds; $18,480 of it was for drugs given in the office and $158,803 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 367 | 5,739 | 75 | 1.24 | $877,946 | $177,283 |
| 2023 | 273 | 2,918 | 75 | 1.22 | $517,198 | $106,698 |
| 2022 | 384 | 3,079 | 74 | 1.11 | $764,066 | $148,916 |
| 2021 | 317 | 1,704 | 74 | 1.22 | $525,681 | $116,048 |
| 2020 | 164 | 532 | 72 | 1.39 | $238,064 | $40,698 |
| 2019 | 49 | 118 | 65 | 2.77 | $71,183 | $6,642 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Return visit (30+ min) | 130 | $21,151 | $106 |
| New patient visit (45+ min) | 74 | $10,383 | $140 |
| Botox | 13 | $8,464 | None |
| Insertion of lower leg neurostimulator electrode | 12 | $8,131 | $108 |
| Diagnostic exam of bladder and urethra using an endoscope | 27 | $6,626 | $214 |
| New patient visit (60+ min) | 34 | $6,376 | $188 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 13 | $4,934 | $352 |
| Short return visit (20+ min) | 58 | $4,574 | $68 |
| Long return visit (40+ min) | 26 | $4,154 | $154 |
| Insertion of sacral nerve neurostimulator electrode array | 11 | $2,881 | $262 |
| Insertion or replacement of peripheral, sacral, or gastric neurostimulator generator or receiver | 11 | $1,499 | $136 |
| Urinalysis, manual test | 213 | $1,224 | $3 |
| New patient visit (30+ min) | 12 | $1,158 | $96 |
| Ultrasound measurement of bladder capacity after voiding | 98 | $1,029 | $10 |
2022: 20 services
| Short return visit (20+ min) | 167 | $17,423 | $74 |
| Return visit (30+ min) | 119 | $16,418 | $108 |
| New patient visit (45+ min) | 115 | $15,367 | $134 |
| Insertion of lower leg neurostimulator electrode | 20 | $13,038 | $110 |
| Diagnostic exam of bladder and urethra using an endoscope | 46 | $11,887 | $212 |
| Injection of implant material beneath lining of bladder and/or urethra using an endoscope | 17 | $5,956 | $331 |
| New patient visit (60+ min) | 31 | $5,369 | $173 |
| Insertion of sacral nerve neurostimulator electrode array | 14 | $3,860 | $257 |
| Injectable bulking agent, synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies | 15 | $3,597 | $189 |
| New patient visit (30+ min) | 45 | $3,538 | $79 |
| Ultrasound measurement of bladder capacity after voiding | 212 | $2,253 | $9 |
| Insertion or replacement of peripheral, sacral, or gastric neurostimulator generator or receiver | 16 | $2,084 | $130 |
| Insertion of device into abdomen with pressure and urine flow rate study | 11 | $2,084 | $189 |
| Urinalysis, manual test | 312 | $1,959 | $3 |
| Long return visit (40+ min) | 14 | $1,873 | $134 |
| Insertion of stent in ureter using an endoscope | 12 | $1,582 | $105 |
| Simple bladder irrigation and/or instillation | 11 | $1,068 | $71 |
| Short return visit | 11 | $542 | $49 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $343 | $20 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 11 | $317 | $29 |
2021: 17 services
| New patient visit (45+ min) | 92 | $12,685 | $138 |
| New patient visit (60+ min) | 66 | $12,007 | $182 |
| Diagnostic exam of bladder and urethra using an endoscope | 53 | $11,887 | $212 |
| Short return visit (20+ min) | 100 | $10,973 | $77 |
| Return visit (30+ min) | 63 | $8,485 | $110 |
| Insertion of lower leg neurostimulator electrode | 19 | $4,780 | $120 |
| Injection of implant material beneath lining of bladder and/or urethra using an endoscope | 12 | $4,334 | $333 |
| New patient visit (30+ min) | 47 | $4,286 | $91 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 12 | $4,064 | $339 |
| Long return visit (40+ min) | 14 | $2,382 | $159 |
| Insertion of device into abdomen with pressure and urine flow rate study | 13 | $2,313 | $178 |
| Ultrasound measurement of bladder capacity after voiding | 131 | $1,469 | $9 |
| Urinalysis, manual test | 199 | $1,124 | $3 |
| Short return visit | 17 | $775 | $46 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 13 | $357 | $27 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $314 | $21 |
| Electronic assessment of bladder emptying | 13 | $80 | $6 |
2020: 13 services
| New patient visit (45+ min) | 33 | $4,527 | $137 |
| Diagnostic exam of bladder and urethra using an endoscope | 23 | $4,421 | $192 |
| New patient visit (30+ min) | 32 | $2,787 | $87 |
| New patient visit (60+ min) | 11 | $1,981 | $180 |
| Return visit (30+ min) | 15 | $1,609 | $95 |
| Short return visit (20+ min) | 15 | $1,055 | $66 |
| Insertion of device into abdomen with pressure and urine flow rate study | 14 | $408 | $29 |
| Urinalysis, manual test | 81 | $383 | $3 |
| Ultrasound measurement of bladder capacity after voiding | 36 | $343 | $10 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 14 | $193 | $14 |
| Injection procedure for imaging of bladder during voiding | 14 | $191 | $14 |
| Review by radiologist of urinary bladder and urethra images with contrast and after passing urine | 14 | $167 | $12 |
| Electronic assessment of bladder emptying | 13 | $44 | $3 |
Medicaid work
$2,319 in 2024
Medicaid paid $2,319 for 113 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 16 | $2,198 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 97 | $121 |
| 2024 | 113 | 2 | 22 | $2,319 |
| 2023 | 274 | 4 | 28 | $5,476 |
| 2022 | 204 | 2 | 24 | $670 |
| 2021 | 41 | 1 | 13 | $51 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 44 | $3,374 |
| New patient visit (45+ min) | 13 | $1,635 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 189 | $236 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 28 | $232 |
2022
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 43 | $444 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 161 | $226 |
2021
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 41 | $51 |
Drugs they prescribed that Part D paid
$203,384
Pharmacies billed $203,384 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (15 of 906) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
622 generic and fewer than 11 brand-name prescriptions · $203,384 in drug cost · 159 antibiotic prescriptions to 87 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 133 | $81,354 | $612 |
| Gemtesa | 121 | $80,118 | $662 |
| Estradiol | 190 | $12,171 | $64 |
| Estring | 13 | $6,738 | $518 |
| Fosfomycin Tromethamine | 21 | $4,624 | $220 |
See all 15 drugs
| Myrbetriq | 133 | $81,354 | $612 |
| Gemtesa | 121 | $80,118 | $662 |
| Estradiol | 190 | $12,171 | $64 |
| Estring | 13 | $6,738 | $518 |
| Fosfomycin Tromethamine | 21 | $4,624 | $220 |
| Methenamine Hippurate | 43 | $4,305 | $100 |
| Trospium Chloride | 23 | $865 | $38 |
| Tamsulosin | 79 | $829 | $10 |
| Nitrofurantoin Mono-Macro | 24 | $459 | $19 |
| Oxybutynin Chloride Er | 15 | $344 | $23 |
| Cephalexin | 60 | $307 | $5 |
| Nitrofurantoin | 11 | $187 | $17 |
| Amoxicillin-Clavulanate Potass | 13 | $172 | $13 |
| Tadalafil | 11 | $167 | $15 |
| Sulfamethoxazole-Trimethoprim | 14 | $41 | $3 |
Year by year
| 2024 | 906 | 276 | 2% (15) | None | $203,384 |
| 2023 | 617 | 192 | None | None | $185,750 |
| 2022 | 785 | 232 | 2% (12) | None | $191,243 |
| 2021 | 467 | 172 | None | None | $94,269 |
| 2020 | 222 | 84 | None | None | $34,781 |
| 2019 | 47 | 31 | None | 28% | $5,687 |
| 2018 | 32 | 18 | None | None | $211 |
| 2017 | 101 | 65 | 29% (29) | None | $3,508 |
| 2016 | 49 | 34 | 41% (20) | None | $350 |
| 2015 | 81 | 47 | 36% (29) | None | $547 |
| 2014 | 56 | 22 | 0% (0) | None | $2,719 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Myrbetriq | 151 | $96,984 | $642 |
| Gemtesa | 83 | $59,005 | $711 |
| Estradiol | 108 | $10,632 | $98 |
| Methenamine Hippurate | 39 | $4,575 | $117 |
| Tamsulosin | 48 | $1,062 | $22 |
| Finasteride | 13 | $375 | $29 |
| Cephalexin | 45 | $298 | $7 |
| Nitrofurantoin | 17 | $285 | $17 |
| Nitrofurantoin Mono-Macro | 14 | $237 | $17 |
| Sulfamethoxazole-Trimethoprim | 12 | $51 | $4 |
2022: 12 drugs
| Myrbetriq | 216 | $112,123 | $519 |
| Gemtesa | 78 | $39,569 | $507 |
| Estradiol | 133 | $13,893 | $104 |
| Premarin | 15 | $6,620 | $441 |
| Methenamine Hippurate | 26 | $4,485 | $172 |
| Trospium Chloride Er | 18 | $3,884 | $216 |
| Tamsulosin | 84 | $1,342 | $16 |
| Finasteride | 32 | $995 | $31 |
| Nitrofurantoin Mono-Macro | 22 | $355 | $16 |
| Sulfamethoxazole-Trimethoprim | 34 | $115 | $3 |
| Cephalexin | 18 | $107 | $6 |
| Tramadol | 11 | $29 | $3 |
2021: 9 drugs
| Myrbetriq | 124 | $65,385 | $527 |
| Estradiol | 93 | $12,054 | $130 |
| Premarin | 13 | $5,946 | $457 |
| Methenamine Hippurate | 17 | $3,573 | $210 |
| Finasteride | 25 | $738 | $30 |
| Tamsulosin | 38 | $616 | $16 |
| Oxybutynin Chloride Er | 13 | $179 | $14 |
| Sulfamethoxazole-Trimethoprim | 38 | $123 | $3 |
| Cephalexin | 17 | $80 | $5 |
2020: 5 drugs
| Myrbetriq | 49 | $22,889 | $467 |
| Estradiol | 22 | $3,059 | $139 |
| Methenamine Hippurate | 17 | $1,952 | $115 |
| Finasteride | 29 | $748 | $26 |
| Tamsulosin | 29 | $584 | $20 |
2018: 1 drug
| Tamsulosin | 13 | $103 | $8 |
2017: 3 drugs
| Oxycodone-Acetaminophen | 11 | $81 | $7 |
| Acetaminophen-Codeine | 11 | $50 | $5 |
| Cephalexin | 14 | $39 | $3 |
2016: 2 drugs
| Ciprofloxacin | 12 | $53 | $4 |
| Acetaminophen-Codeine | 12 | $49 | $4 |
2015: 2 drugs
| Oxycodone-Acetaminophen | 19 | $169 | $9 |
| Ciprofloxacin | 22 | $71 | $3 |
Money from drug and device companies
$11,710 in 2025
| 2025 | 4 | 9 | $10,530 | $11,710 |
| 2024 | 5 | 22 | $17,655 | $20,542 |
| 2023 | 3 | 11 | $8,215 | $9,007 |
| 2022 | 3 | 10 | None | $637 |
| 2021 | 3 | 11 | None | $468 |
| 2020 | 3 | 5 | None | $270 |
| 2019 | 4 | 17 | None | $1,543 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Valencia Technologies | Ecoin Device Kit | $11,460 | 4 payments
|
| Ambu | None | $90 | 1 payment
|
| Medtronic | Venaseal | $85 | 1 payment
|
| Abbvie | Botox | $75 | 3 payments
|
See all 9 published payments
| Medtronic | Meals · 2025-08-27 | Venaseal | $85 |
| Abbvie | Meals · 2025-07-18 | Botox | $28 |
| Valencia Technologies | Consulting · 2025-06-27 | Ecoin Device Kit | $9,945 |
| Valencia Technologies | Travel · 2025-06-05 | Ecoin Device Kit | $864 |
| Valencia Technologies | Meals · 2025-06-05 | Ecoin Device Kit | $66 |
| Abbvie | Meals · 2025-05-01 | Botox | $30 |
| Ambu | Meals · 2025-04-16 | None | $90 |
| Valencia Technologies | Consulting · 2025-03-27 | Ecoin Device Kit | $585 |
| Abbvie | Meals · 2025-03-20 | Botox | $18 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $20,542
| Valencia Technologies | Ecoin Device Kit | $20,143 | 15 payments
|
| Teleflex | Urolift | $211 | 3 payments
|
| Boston Scientific | Lithovue | $151 | 2 payments
|
| Abbvie | Botox | $18 | 1 payment
|
| Urogen Pharma | Jelmyto | $18 | 1 payment
|
2023: $9,007
| Valencia Technologies | Ecoin Device Kit | $8,850 | 6 payments
|
| Axonics | Axonics | $141 | 4 payments
|
| Abbvie | Botox | $17 | 1 payment
|
2022: $637
| Valencia Technologies | Ecoin Device Kit | $296 | 1 payment
|
| Axonics | Axonics | $223 | 8 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $119 | 1 payment
|
2021: $468
| Axonics | Bulkamid | $403 | 9 payments
|
| Medtronic | Interstim | $44 | 1 payment
|
| Boston Scientific | Lynx | $22 | 1 payment
|
2020: $270
| Boston Scientific | Advantage Fit | $137 | 3 payments
|
| Allergan | Botox | $119 | 1 payment
|
| Medtronic USA | Interstim Icon | $14 | 1 payment
|
2019: $1,543
| Boston Scientific | Erectile Dysfunction | $1,157 | 13 payments
|
| Medtronic USA | Interstim | $219 | 2 payments
|
| Blue Earth Diagnostics | Axumin | $115 | 1 payment
|
| Astellas Pharma US | Xtandi | $53 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 96.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1437562964
- Licence
- CA 20A18235
- Trained
- Philadelphia College of Osteopathic Medicine, 2014
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 3400 Data Dr, Attn Credentialing/Payer Enrollment, Rancho Cordova, CA, 95670
- NPI first listed
- 2014-06-02
- NPI last updated
- 2026-09-10
- NPI record certified
- 2026-09-10
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 195 Page Mill Rd Ste 103, Palo Alto, CA, 94306